The QIAGENcares Program — Making Improvements in Life Possible
  • Main Image Navi

Our QIAGENcares program aims to improve access to screening methods for infectious diseases in emerging and developing countries. Under the program, QIAGEN will join forces with organizations to extend the fight against disease across the globe. The current focus is on projects helping to improve the lives of women around the world by expanding access to screening technologies and working to eliminate cervical cancer. We seek innovative public-private partnerships with global organizations, leading clinicians and experts, other corporate partners, and women’s advocacy groups that will work together enabling women to be forever free of this disease.

Read more about QIAGEN’s commitment to eliminating cervical cancer

QIAGEN has announced the following initiatives for the QIAGENcares program:

  

careHPV

To ensure that HPV testing is practical, effective, and affordable for women in all regions of the world, QIAGEN is working with PATH and the Bill & Melinda Gates Foundation to develop a new version of its state-of-the-art, HPV test — to be called the careHPV Test — for public-health programs in low-resource, developing countries. The careHPV Test, currently in development, can be performed without electricity or running water and offers HPV detection results in a matter of hours — a critical characteristic for women traveling to clinics from isolated villages and for those women who may need to be treated the same day. Both QIAGEN HPV screening technologies — careHPV and the digene HPV Test - are expected to play a key role in reducing cervical cancer worldwide.

Read more about the careHPV Test — Expanding access to cervical cancer screening technologies

Read QIAGEN's press release about careHPV development

 

Donation of 1 million tests to the world's poorest countries

QIAGEN will be donating 1 million HPV tests to bring cervical cancer screening to the world's poorest nations. The HPV tests will be donated over a five-year period and directed among the world's poorest countries as determined by national income and gross national income. QIAGEN will be meeting with global health advocates and public health partners to ensure efficient distribution of the donated HPV tests to appropriate recipients. An international advisory board of NGO leaders will provide oversight to the donation program to ensure equity and transparency for the process.

Read QIAGEN's press release about its donation here

For more information about the donation program, please email: QIAGEN.cares@qiagen.com
 

QIAGEN-Merck collaboration to accelerate access to cervical cancer prevention

As part of its commitment to ensuring access to cervical cancer prevention, QIAGEN announced an exciting new collaboration with HPV vaccine developer Merck to provide HPV DNA testing and HPV vaccination to women and girls in the most resource-poor areas of the world.  Through this initiative, Merck will provide up to 5 million doses of the vaccine free of charge and QIAGEN will expand its existing one million HPV test donation program by 500,000 to screen a total of 1.5 million women in the developing world. 


Read the press release about the QIAGEN/Merck collaboration

Bringing cervical cancer screening to India

QIAGEN is partnering with the Chittaranjan National Cancer Institute (CNCI) to bring the benefits of cervical cancer screening and HPV testing to women in Kolkata, India via an initiative called the QIAGENcares Kolkata Screening Project. The initiative will be conducted over 5 years and is expected to provide cervical cancer screening to 50,000 women. Through this program, awareness about cervical cancer prevention will be increased and screening made more accessible, two vital ingredients in the effort to reduce the high cervical cancer rates in India.

 
Read QIAGEN’s press release about the launch of the QIAGENcares Kolkata initiative here

Donation of HPV tests to China

For the fourth year in a row, QIAGEN and the Cancer Foundation of China are joining hands on March 8th, International Women’s Day, to raise awareness about cervical cancer and provide preventative screening.  This year, QIAGEN is again donating its “gold standard” human papillomavirus (HPV) molecular diagnostic test for the screening of several thousand underprivileged women across China. The free testing program is part of the larger “3.8 Program” – a nationwide cancer prevention campaign organized by the Cancer Foundation of China and partially sponsored by QIAGEN.

Over the last 3 years of the collaboration approximately 10,000 women have been screened with QIAGEN’s digene HPV Test and statistics for over half of these women have been reported. Of those reported, a total of 120 were found to have mild dysplasia (abnormal cell growth) due to HPV infection (CIN1), 27 had moderate dysplasia (CIN2), 4 had severe dysplasia (CIN3) and 6 were found to have invasive cervical cancer. All women diagnosed with CIN2/3 and cancer were referred to local medical centers for further diagnosis and surgery if appropriate.

Through this screening program, to date QIAGEN has helped to improve the lives of 157 women who might otherwise have gone on to develop and/or perish from cervical cancer. This is a perfect example of how QIAGEN technology truly makes improvements in life possible.
 

The Global Burden of Cervical Cancer

Worldwide, cervical cancer affects approximately 500,000 women annually and, after breast cancer, is the second-most-common malignancy found in women. Since the cause of cervical cancer — human papillomavirus (HPV) — is known and women who have it can be identified, it is a highly preventable and treatable disease if women have access to organized prevention programs. However, the World Health Organization estimates that only about 5 percent of women in the developing world have been screened for cervical disease in the previous five years, compared to 40–50 percent in the developed world.

For More Information

For more information on QIAGENcares and the donation program, send an e-mail to QIAGEN.cares@qiagen.com